Adverse events associated with the use of insulins glulisine, aspart and glargine: a literature review
DOI:
https://doi.org/10.56294/hl2024.503Keywords:
health, cardiovascular disease, blindness, patientAbstract
The objective of this article was to identify adverse events that are generated as a result of the use of insulins Aspart, Glargine and Glulisine in patients with type 2 diabetes mellitus. For this purpose, an exhaustive bibliographic review was carried out in the Scopus and PubMed databases. Inclusion criteria were applied that limited the selection to open access controlled clinical trials that addressed the safety of the aforementioned insulins, excluding those articles that did not contain relevant information. 22 scientific articles were selected that were located in a total of 13 journals. 11 documents dealt with the topic of Insulin Glargine, 7 on Aspart and 4 on Glulisine. The year where most articles were found was 2019 (5). In total, 14 types of adverse events were identified, with hypoglycemia being the most representative with 39 cases and the event with the highest incidence of up to 62%. It is concluded that insulins, glargine, glulisine and aspart present a variety of adverse reactions, with hypoglycemic events being the most prevalent, especially with insulin aspart (0.006% - 62%). Other common effects include nausea, diarrhea and vomiting, with a higher incidence in treatments with glargine and aspartate.
References
1. Almigbal TH, Alzarah SA, Aljanoubi FA, Alhafez NA, Aldawsari MR, Alghadeer ZY, et al. Clinical Inertia in the Management of Type 2 Diabetes Mellitus: A Systematic Review. Medicina (B Aires). 16 de enero de 2023;59(1):182.
2. Organización Mundial de la Salud (OMS). Informe Mundial Sobre la Diabetes [Internet]. Vol. 3, Informe Mundial Sobre la Diabetes. 2016. 71-76 p. Disponible en: https://www3.paho.org/hq/index.php?option=com_content&view=article&id=6717:2012-about-diabetes&Itemid=0&lang=es#gsc.tab=0
3. Rahman MS, Hossain KS, Das S, Kundu S, Adegoke EO, Rahman MA, et al. Role of Insulin in Health and Disease: An Update. Int J Mol Sci. 15 de junio de 2021;22(12):6403.
4. Seetharaman R, Pawar S, Advani M. One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus. Br J Clin Pharmacol. 29 de abril de 2022;88(4):1598-612.
5. Zeynaloo E, Stone LD, Dikici E, Ricordi C, Deo SK, Bachas LG, et al. Delivery of therapeutic agents and cells to pancreatic islets: Towards a new era in the treatment of diabetes. Mol Aspects Med. febrero de 2022;83:101063.
6. Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, et al. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial. Diabetes Technol Ther. 2020;22(7):516-26.
7. Pfohl M, Seufert J, Borck A, Bramlage P, Siegmund T. Effectiveness and Safety of Insulin Glulisine When Initiating Supplemental Prandial Insulin Treatment (SIT) in Insulin-Naïve Type 2 Diabetes Patients: The IGLU-SIT Observational Study. Diabetes Ther. 2021;(12):733-47.
8. Rayner CK, Wu T, Aroda VR, Whittington C, Kanters S, Guyot P, et al. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis. Diabetes, Obes Metab. 2021;23(1):136-46.
9. Trujillo JM, Roberts M, Dex T, Chao J, White J, LaSalle J. Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Diabetes, Obes Metab. 2018;20(11):2690-4.
10. Zhang T, Ji L, Gao Y, Zhang P, Zhu D, Li X, et al. Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors.
Published
Issue
Section
License
Copyright (c) 2024 Alexandra Meneses-Torres, Melissa Inés Mosquera-Soto, Ana Karina Niampira-Piedrahita, Marcela Ceballos-Amaya (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
